Can anyone provide more insight into Pfizer’s pipeline? I have not done a deep dive yet into the pipeline but the company’s fundamentals are interesting (not strong but enough to make you feel safe in the price paid today)
The company’s financials briefly
Forward P/E <9
Trailing p/e \~14-15
P/B \~1.5
Gross margin sits around 75% and operating around 25%
ROE \~10
The debt load is substantial since the mergers (debt to equity is at 0.66) but the company seems to clearly be in a transition phase
Intrest coverage sits around 9.8x - which so long as revenue is stable they can comfortably pay off their debt
The biggest issue to me though is that dividend which FCF has sometimes dipped below 9.8 billion (close to the cost of the dividend anually)
They do have this 4 billion dollar cost cutting program which might save the dividend??
**Some commentary from me.**
The stocks clearly in a transition phase since the glory days of the virus. Overall the stock seems to be priced fairly if the company were to never grow again. Which implies that the mergers basically lead to equal profits as the money being brought in today.
Eliquis and Ibrance patents are coming up due relatively soon. Which is concerning but they are clearly being aggressive in their pipeline ventures.
**Just some commentary as a pharmacist in Canada.**
Covid clearly is here to stay. The vaccine is always in supply - provincial coverage is starting to die down but private drug coverage is starting to fill in these gaps. I work for a top 5 insurance provider here and it seems like the uptake for the vaccine and the revenue it generates will be relatively stable (from a Canadian lens - ik Americans tend to be more adverse to vaccines).
**Questions I have if anyone can help answer**
Any drugs in the pipeline which intrigue you?
Any thoughts on the current drugs they have on the glp space?
Any commentary on the financial health of the dividend?
Thank you!